Efficacy and safety of BNT162b2 mRNA vaccine in a cohort of 90 transfusion dependent thalassemia patients

被引：1
|
作者：
Marziali, M. [1 ]
Pugliese, P. [1 ]
Losardo, A. A. [1 ]
Ribersani, M. [2 ]
Anastasi, E. [3 ]
Angeloni, A. [3 ]
Pavan, A. [1 ]
Gentile, G. [4 ]
机构：
[1] Sapienza Univ Roma, Immunohematol & Transfus Med Unit, Policlin Umberto 1, Rome, Italy
[2] Sapienza Univ Roma, Hematol, Policlin Umberto 1, Rome, Italy
[3] Sapienza Univ Roma, Dept Expt Med, Policlin Umberto 1, Rome, Italy
[4] Sapienza Univ Roma, Dept Translat & Precis Med, Rome, Italy
来源：
TRANSFUSION MEDICINE | 2024年 / 34卷 / 03期
关键词：
Covid-19; Efficacy; Safety; Thalassemia; Vaccine; ANTIBODIES;
D O I：
10.1111/tme.13038
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：238 / 240
页数：3
相关论文
共 50 条
  • [1] Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine
    del Saz, Borja Somovilla
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (12)
  • [2] COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
    Tanzilli, Antonio
    Pace, Andrea
    Ciliberto, Gennaro
    La Malfa, Antonia Marina
    Buonomo, Valentina
    Benincasa, Dario
    Biscu, Annamaria
    Galie, Edvina
    Villani, Veronica
    NEUROLOGICAL SCIENCES, 2022, 43 (06) : 3519 - 3522
  • [3] COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
    Antonio Tanzilli
    Andrea Pace
    Gennaro Ciliberto
    Antonia Marina La Malfa
    Valentina Buonomo
    Dario Benincasa
    Annamaria Biscu
    Edvina Galiè
    Veronica Villani
    Neurological Sciences, 2022, 43 : 3519 - 3522
  • [4] A Prospective Study Regarding the Efficacy and Safety of the BNT162b2 Vaccine in Patients With Solid Malignancies Undergoing Systemic Chemotherapy
    Yamasaki, Eiki
    Shimamoto, Fukutaro
    Nishikawa, Hiroki
    Goto, Masahiro
    Iwamoto, Mitsuhiko
    Kimura, Kosei
    Ukimura, Akira
    Oosaka, Naofumi
    Taniguchi, Koheli
    Ono, Fumihito
    Terazawa, Tetsuji
    Yamaguchi, Toshifumi
    Asaishi, Ken
    Ikegami, Takako
    Uchiyama, Kazuhisa
    Nakamura, Shiro
    Higuchi, Kazuhide
    IN VIVO, 2022, 36 (06): : 2780 - 2789
  • [5] Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
    Saciuk, Yaki
    Kertes, Jennifer
    Stein, Naama Shamir
    Zohar, Anat Ekka
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (01) : 30 - 33
  • [6] Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
    Choe, Young June
    Yi, Seonju
    Hwang, Insob
    Kim, Jia
    Park, Young-Joon
    Cho, Eunhee
    Jo, Myoungyoun
    Lee, Hyunju
    Choi, Eun Hwa
    VACCINE, 2022, 40 (05) : 691 - 694
  • [7] Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever
    Shechtman, Liran
    Lahad, Karney
    Livneh, Avi
    Grossman, Chagai
    Druyan, Amit
    Giat, Eitan
    Lidar, Merav
    Freund, Sarit
    Manor, Uri
    Pomerantz, Alon
    Veroslavski, Daniel
    Ben-Zvi, Ilan
    RHEUMATOLOGY, 2022, 61 (SI2) : SI129 - SI135
  • [8] Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study
    Itzhaki Ben Zadok, Osnat
    Shaul, Aviv A.
    Ben-Avraham, Binyamin
    Yaari, Vicky
    Ben Zvi, Haim
    Shostak, Yael
    Pertzov, Barak
    Eliakim-Raz, Noa
    Abed, Galia
    Abuhazira, Miriam
    Barac, Yaron D.
    Mats, Israel
    Kramer, Mordechai R.
    Aravot, Dan
    Kornowski, Ran
    Ben-Gal, Tuvia
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (09) : 1555 - 1559
  • [9] Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
    Ucciferri, Claudio
    Vecchiet, Jacopo
    Auricchio, Antonio
    Falasca, Katia
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2022, 14
  • [10] Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
    Mansanguan, Suyanee
    Charunwatthana, Prakaykaew
    Piyaphanee, Watcharapong
    Dechkhajorn, Wilanee
    Poolcharoen, Akkapon
    Mansanguan, Chayasin
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2022, 7 (08)
12345